PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER

被引：0
|
作者：
Beauchemin, C. [1 ]
Cooper, D. [2 ]
Lapierre, M. E. [1 ]
Yelle, L. [3 ]
Lachaine, J. [1 ]
机构：
[1] Univ Montreal, Montreal, PQ, Canada
[2] INESSS, Quebec City, PQ, Canada
[3] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A414 / A414
页数：1
相关论文
共 50 条
  • [31] Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
    Belin, Lisa
    Tan, Aidan
    De Rycke, Yann
    Dechartres, Agnes
    [J]. BRITISH JOURNAL OF CANCER, 2020, 122 (11) : 1707 - 1714
  • [32] Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
    Lisa Belin
    Aidan Tan
    Yann De Rycke
    Agnès Dechartres
    [J]. British Journal of Cancer, 2020, 122 : 1707 - 1714
  • [33] The validity of progression-free survival 2 as a surrogate trial end point for overall survival
    Woodford, Rachel G.
    Zhou, Deborah D. X.
    Kok, Peey-Sei
    Lord, Sally J.
    Friedlander, Michael
    Marschner, Ian C.
    Simes, R. John
    Lee, Chee Khoon
    [J]. CANCER, 2022, 128 (07) : 1449 - 1457
  • [34] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
    Stewart, D.
    Bosse, D.
    Ocana, A.
    Goss, G.
    Jonker, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782
  • [35] Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma
    Negrier, S.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Korytowsky, B.
    Sandin, R.
    Charbonneau, C.
    Michaelson, M. D.
    Figlin, R. A.
    Motzer, R. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (10) : 1766 - 1771
  • [36] A meta-analysis of randomized, controlled trials in metastatic melanoma establishes progression-free survival as a surrogate for overall survival
    Flaherty, K. T.
    Lee, S. J.
    Dummer, R.
    Hauschild, A.
    Hennig, M.
    Long, G. V.
    Lorigan, P.
    Robert, C.
    Schadendorf, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S856 - S856
  • [37] Doubling time of progression-free survival by palbociclib in metastatic breast cancer
    L'Allemain, Gilles
    [J]. BULLETIN DU CANCER, 2015, 102 (04) : 300 - 300
  • [38] Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
    Rochefort, Pauline
    Chabaud, Sylvie
    Pierga, Jean-Yves
    Tredan, Olivier
    Brain, Etienne
    Bidard, Francois-Clement
    Schiffler, Camille
    Polena, Helena
    Khalil-Mgharbel, Abir
    Vilgrain, Isabelle
    Bachelot, Thomas
    [J]. BRITISH JOURNAL OF CANCER, 2017, 116 (03) : 356 - 361
  • [39] Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
    Pauline Rochefort
    Sylvie Chabaud
    Jean-Yves Pierga
    Olivier Tredan
    Etienne Brain
    François-Clément Bidard
    Camille Schiffler
    Helena Polena
    Abir Khalil-Mgharbel
    Isabelle Vilgrain
    Thomas Bachelot
    [J]. British Journal of Cancer, 2017, 116 : 356 - 361
  • [40] Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer
    Chirila, Costel
    Odom, Dawn
    Devercelli, Giovanna
    Khan, Shahnaz
    Sherif, Bintu N.
    Kaye, James A.
    Molnar, Istvan
    Sherrill, Beth
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2012, 27 (05) : 623 - 634
12345